Author
Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.
6 papers
Recent·Most cited
D. M. Dolivo, A. E. Rodrigues, R. D. Galiano, T. A. Mustoe, S. J. Hong
The paper identifies LINC01013 as a marker of fibroblast activation using transcriptomic data from healthy and diseased tissues.
bioRxiv · Mar 21, 2023 · PreprintCell Biology
S. Iketani, H. Mohri, B. Culbertson, S. J. Hong, Y. Duan, M. I. Luck, M. K. Annavajhala, Y. Guo, Z. Sheng, A.-C. Uhlemann, S. P. Goff, Y. Sabo, H. Yang, A. Chavez, D. D. Ho
This study identifies multiple mutational pathways leading to nirmatrelvir resistance in SARS-CoV-2 through in vitro experiments and structural analysis.
bioRxiv · Aug 7, 2022Microbiology
S. Iketani, S. J. Hong, J. Sheng, F. Bahari, B. Culbertson, F. F. Atanaki, A. K. Aditham, A. F. Kratz, M. I. Luck, R. Tian, S. P. Goff, H. Montazeri, Y. Sabo, D. D. Ho, A. Chavez
This study maps the functional landscape of SARS-CoV-2 3CL protease by profiling all single mutants and identifies resistance mutations to nirmatrelvir.
bioRxiv · Jun 23, 2022 · PreprintMicrobiology
S. J. Resnick, S. Iketani, S. J. Hong, A. Zask, H. Liu, S. Kim, S. Melore, M. S. Nair, Y. Huang, N. E. S. Tay, T. Rovis, H. W. Yang, B. R. Stockwell, D. D. Ho, A. Chavez
This paper introduces a cell-based assay to identify coronavirus 3CL protease inhibitors without live virus, demonstrating its effectiveness through compound screening and structure-activity profiling.
bioRxiv · Aug 29, 2020 · PreprintMicrobiology
S. Iketani, F. Forouhar, H. Liu, S. J. Hong, F.-Y. Lin, M. S. Nair, A. Zask, Y. Huang, L. Xing, B. R. Stockwell, A. Chavez, D. D. Ho
The paper identifies three structurally diverse compounds as inhibitors of the SARS-CoV-2 3CL protease and provides structural insights for inhibitor design.
bioRxiv · Aug 3, 2020Microbiology
N. Singh, O. Shestova, P. Ravikumar, K. Hayer, S. J. Hong, E. J. Orlando, K. T. Mueller, C. R. Good, S. L. Berger, O. Shalem, M. D. Weitzman, S. A. Grupp, C. H. June, S. Gill, M. Ruella
This study identifies impaired death receptor signaling as a driver of resistance to CAR T cell therapy in B-cell leukemia by showing its role in tumor survival and T cell dysfunction.
bioRxiv · May 5, 2019 · PreprintImmunology